Abstract
In The Lancet Infectious Diseases, Henry J C de Vries and colleagues 1 de Vries HJC de Laat M Jongen VW et al. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial. Lancet Infect Dis. 2022; (published online Jan 19.)https://doi.org/10.1016/S1473-3099(21)00625-3 Summary Full Text Full Text PDF Scopus (5) Google Scholar report exciting results from their New AntiBiotic treatment Options for uncomplicated GOnorrhea (NABOGO) randomised controlled trial. This non-inferiority trial examined the efficacy of single doses of ertapenem 1 g (intramuscularly), gentamicin 5 mg/kg (max 400 mg, intramuscularly) or fosfomycin 6 g (oral solution) compared with ceftriaxone 500 mg (intramuscularly) for the treatment of uncomplicated anogenital Neisseria gonorrhoeae. Secondary analyses examined efficacy at the pharynx. This trial is important because new treatments to treat resistant N gonorrhoeae are some way off and repurposing existing registered drugs remains the only option. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trialSingle-dose 1000 mg ertapenem is non-inferior to single-dose 500 mg ceftriaxone in gonorrhoea treatment. Yet, 5 mg/kg gentamicin (maximum 400 mg) is not non-inferior to ceftriaxone. Ertapenem is a potential effective alternative for anogenital N gonorrhoeae infections and merits evaluation for ceftriaxone-resistant infections. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
